Abstract: Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.
Type:
Grant
Filed:
December 2, 1998
Date of Patent:
March 9, 2004
Assignee:
AutoImmune Inc.
Inventors:
Howard L. Weiner, George Eisenbarth, David Allen Hafler, Zhengyi Zhang
Abstract: Described are methods for treating or preventing type I diabetes and insulitis by oral administration of the bystander antigen glucagon. The methods involve oral administration of glucagon in an amounts that are effective to treat or prevent type I diabetes or insulitis.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
November 11, 2003
Assignee:
AutoImmune Inc.
Inventors:
Howard Weiner, Ariel Miller, Zhengyi Zhang, Ahmad Al-Sabbagh
Abstract: The invention relates to a treatment for multiple sclerosis. COP-1 (copolymer-1), a synthetic polymer consisting of a mixture of random synthetic polypeptides composed of L-alanine, L-glutamic acid, L-lysine and L-tyrosine in a molar ratio of about 6:2:5:1, is administered mucosally to patients afflicted with the disease in combination with Th2 enhancing cytokines such as IL-4 or IL-10. The combination treatment of IL-4 or IL-10 (preferably orally administered) with mucosally administered COP-1 shows a substantially greater suppressive effect than does treatment with cytokine or COP-1 alone.
Type:
Application
Filed:
February 6, 2001
Publication date:
July 12, 2001
Applicant:
Autoimmune, Inc.
Inventors:
Howard L. Weiner, Ruth Marron, Anthony Slavin
Abstract: Peptides containing regions of myelin basic protein found in the 86-102 and 143-168 sequences that are immunodominant in humans suffering from multiple sclerosis.
Abstract: Peptides containing immunodominant epitopes of myelin basic protein that are recognized by groups of T-cells from remitting-relapsing multiple sclerosis patients.
Abstract: Peptides are administered to individuals suffering from multiple sclerosis. The peptides contain immunodominant epitopes of myelin basic protein that are recognized by T-cells from relapsing-remitting multiple sclerosis patients, and that are contained in the 84-102 and 143-168 regions of human MBP.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
March 14, 2000
Assignee:
Autoimmune, Inc.
Inventors:
Howard L. Weiner, David A. Hafler, Ariel Miller, Ahmad Al-Sabbagh
Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.
Abstract: The present invention provides a method of treating or preventing the clinical manifestation of an autoimmune disease having the symptoms of uveoretinitis in a mammal in need of such treatment comprising orally administering to said mammal an effective amount of an autoantigen, e.g., S antigen (S-Ag), and/or biologically active fragments, or analogs thereof specific for uveoretinitis.Also provided is a pharmaceutical formulation useful for treating or preventing uveoretinitis in mammals comprising an effective amount of one or more of the foregoing autoantigen, fragments or analogs.
Type:
Grant
Filed:
April 10, 1995
Date of Patent:
October 5, 1999
Assignees:
AutoImmune Inc., The United States of America as represented by the Department of Health and Human Services
Inventors:
David Allen Hafler, Robert B. Nussenblatt, Alan G. Palestine, Howard L. Weiner
Abstract: A combination of a mucosally administrable bystander antigen and an orally, enterally, or parenterally administrable methotrexate is employed to make a pharmaceutical formulation and to treat or prevent autoimmune disease.
Type:
Grant
Filed:
January 23, 1998
Date of Patent:
August 10, 1999
Assignee:
Autoimmune Inc.
Inventors:
Howard L. Weiner, Ahmad Al-Sabbagh, Patricia A. Nelson
Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.
Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral or enteral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.
Abstract: Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
January 12, 1999
Assignee:
AutoImmune Inc.
Inventors:
Howard L. Weiner, George Eisenberth, David Allen Hafler, Zhengi Zhang
Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.
Abstract: A method for suppressing autoimmune response in an afflicted joint in a human. The method involves oral administration of between about 5 and 25 .mu.g per day of type II collagen.
Type:
Grant
Filed:
July 5, 1996
Date of Patent:
January 5, 1999
Assignee:
Autoimmune Inc.
Inventors:
Howard L. Weiner, David A. Hafler, David E. Trentham
Abstract: The invention is directed to a method of treating multiple sclerosis in animals, including humans, by the oral administration of bovine myelin.
Abstract: Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
December 1, 1998
Assignee:
Autoimmune, Inc.
Inventors:
Howard L. Weiner, George Eisenbarth, David Allen Hafler, Zhengi Zhang
Abstract: The present invention is directed to a method and pharmaceutical formulations for the treatment of autoimmune arthritis and animal models therefore in mammals, including humans, by the oral, enteral or by-inhalation administration of whole collagen protein or biologically active peptide fragments of collagen.
Abstract: An method is disclosed for removing Type I collagen-containing tissue adjoining Type II collagen-containing animal tissue comprising treatment of unprocessed Type II collagen-containing tissue in an acidic solution in the presence of an acid proteinase and subjecting the mixture to moderate agitation for a period of time sufficient to cause digestion or separation of the Type I collagen-containing tissue from the Type II collagen-containing tissue. Also disclosed are methods for removing proteoglycans from Type II collagen-containing tissue.
Type:
Grant
Filed:
January 3, 1997
Date of Patent:
November 24, 1998
Assignee:
AutoImmune, Inc.
Inventors:
Anna Gunilla Oberg Sturrock, Dale P. Devore
Abstract: An autoantigen identified as HP-8 which is related to systemic lupus erythematosus. The HP-8 antigen is expressed by a gene which was identified by immunoscreening of human placental cDNA GT11 expression library with the monoclonal antibody 3E10. The 3E10 antibody is a low-affinity anti-double-stranded DNA autoantibody derived from the MRL murine models for human systemic lupus erythematosus.
Type:
Grant
Filed:
April 12, 1995
Date of Patent:
September 15, 1998
Assignee:
VivoRx Autoimmune, Inc.
Inventors:
Cynthia K. French, Karen K. Yamamoto, Phoebe M. Chow, Negemias T. Alido